These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7110537)

  • 1. An investigation of the relationship between the dopaminergic and electroencephalographic effects of gamma-butyrolactone.
    Snead OC
    Neuropharmacology; 1982 Jun; 21(6):539-43. PubMed ID: 7110537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate.
    Snead OC; Bearden LJ
    Neurology; 1980 Aug; 30(8):832-8. PubMed ID: 7191065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic gamma-butyrolactone (GBL) treatment: a potential model of dopamine hypoactivity.
    Nowycky MC; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Nov; 309(3):247-54. PubMed ID: 43476
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopaminergic neurons: reversal of effects elicited by gamma-butyrolactone by stimulation of the nigro-neostriatal pathway.
    Murrin LC; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Oct; 295(1):15-20. PubMed ID: 12482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed inhibition of dopamine synthesis by gamma-butyrolactone and baclofen: dopamine autoreceptor supersensitivity?
    Argiolas A; Fadda F; Melis MR; Marcou M; Porceddu ML; Gessa GL
    Eur J Pharmacol; 1982 Nov; 85(1):23-7. PubMed ID: 6818043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not gamma-butyrolactone-resistant dopamine release.
    Chrapusta SJ; Karoum F; Egan MF; Wyatt RJ
    Eur J Pharmacol; 1993 Mar; 233(1):135-42. PubMed ID: 8472742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of autoreceptors on dopamine neurons in different brain regions of rats treated with gammabutyrolactone.
    Andén NE; Grabowska-Andén M; Liljenberg B
    J Neural Transm; 1983; 58(3-4):143-52. PubMed ID: 6420514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceleration of the biosynthesis of rat striatal dopamine by incubation and by administration of gamma-butyrolactone.
    Dyck LE; Kazakoff CW
    J Neurosci Res; 1982; 8(1):57-65. PubMed ID: 7175978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3,4-dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effects and evidence for somatodendritic mechanisms.
    Beart PM; Gundlach AL
    Br J Pharmacol; 1980 Jun; 69(2):241-7. PubMed ID: 6108139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gamma-hydroxybutyrate model of absence seizures: correlation of regional brain levels of gamma-hydroxybutyric acid and gamma-butyrolactone with spike wave discharges.
    Snead OC
    Neuropharmacology; 1991 Feb; 30(2):161-7. PubMed ID: 2030821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.
    Roth RH; Murrin LC; Walters JR
    Eur J Pharmacol; 1976 Mar; 36(1):163-71. PubMed ID: 177297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for down-regulation of GABA receptors following long-term gamma-butyrolactone.
    Gianutsos G; Suzdak PD
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Nov; 328(1):62-8. PubMed ID: 6096730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of striatal dopaminergic functions implicated in methamphetamine-induced reverse tolerance in rats.
    Kaneno S; Watanabe A; Takahashi R
    Eur J Pharmacol; 1986 Apr; 123(2):287-94. PubMed ID: 3086109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
    Feenstra MG; Sumners C; Goedemoed JH; de Vries JB; Rollema H; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(2):108-15. PubMed ID: 6646238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. gamma-Butyrolactone effects on behavior induced by dopamine agonists.
    Ellinwood EH; Gonzalez AE; Dougherty GG
    Biol Psychiatry; 1983 Sep; 18(9):1023-32. PubMed ID: 6685535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced in mouse brain dopamine.
    Gianutsos G; Thornburg JE; Moore KE
    Psychopharmacology (Berl); 1976 Nov; 50(3):225-9. PubMed ID: 826966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum.
    Doherty JD; Simonovic M; So R; Meltzer HY
    Eur J Pharmacol; 1980 Jul; 65(2-3):139-49. PubMed ID: 7398783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse.
    Gianutsos G; Moore KE
    J Pharmacol Exp Ther; 1978 Dec; 207(3):859-69. PubMed ID: 731436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic inhibition of nigrostriatal dopamine release in the mouse: lack of cross tolerance between apomorphine, GBL and CGS 10746B.
    Wood PL; Altar CA; Kim HS
    Life Sci; 1988; 42(16):1503-6. PubMed ID: 3352463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticonvulsant properties of alpha, gamma, and alpha, gamma-substituted gamma-butyrolactones.
    Klunk WE; Covey DF; Ferrendelli JA
    Mol Pharmacol; 1982 Sep; 22(2):438-43. PubMed ID: 7144736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.